안과용 레이저 시장 규모는 2025년에 15억 6,000만 달러에 달할 것으로 추정됩니다. 예측 기간(2025-2030년)의 CAGR은 4.7%를 나타내 2030년에는 19억 6,000만 달러에 달할 것으로 예상되고 있습니다.
COVID-19 팬데믹의 결과, 의료 시스템은 막대한 도전을 목격했습니다. COVID-19 전염병 동안 대부분의 만성 치료는 긴급하지 않은 것으로 간주되었기 때문에 모든 감염 치료의 위험을 줄이기 위해 모든 외래 치료가 연기되거나 제한되었습니다. 2021년 12월 안과 및 시력 연구 저널에 발표된 논문에 따르면 코로나19가 직간접적으로 안구 문제를 일으켰으며, 코로나19 치료의 부작용과 봉쇄령 및 자택 대피령의 간접적인 결과도 우려되는 추가 원인으로 지적되었습니다. 또한 팬데믹에 의한 막대한 이환율과 사망자 수가 합병증이라는 마이너스면을 수반하는 구명치료 프로토콜의 채용으로 이어졌습니다고 기사는 말했습니다. 이러한 장애는 안과용 레이저 시장의 성장에 영향을 미칩니다. 그러나 시장이 열리고 있으며 제품 출시 및 기타 노력으로 예측 기간 동안 성장할 것으로 보입니다.
WHO 2021에 따르면, 세계적으로 적어도 22억 명이 근시 또는 원시 장애를 가지고 있습니다. 해는 교정되지 않은 근시(2,440억 달러)와 노안(254억 달러)에 의한 시력 장애와 관련되어 세계의 경제적 부담이 되고 있습니다.
마찬가지로 2022년 1월 세계경제포럼의 보도 자료에 따르면 근시의 비율은 극적으로 증가했습니다.
주요 시장 기업의 이니셔티브는 예측 기간 동안 시장 성장을 더욱 증가시킬 것으로 예상됩니다. Advance의 특징은 원래 iTrack 장치의 독특한 조명이있는 광섬유 팁을 포함하여 외과 의사가 Schlemm 관에서 장치의 위치를 지속적으로 모니터링 할 수 있도록합니다.
그러나 레이저 치료와 관련된 높은 비용과 숙련된 개업의 가용성이 낮아 예측 기간 동안 조사 시장의 성장을 제한할 것으로 예상됩니다.
굴절 이상 교정 부문이 안과용 레이저 시장에서 큰 점유율을 차지하고 있습니다. Surgery 잡지에 게재된 종이제에 따르면, 굴절이상은 가장 일반적인 시력 문제이며, 중대한 건강 문제인 것이 증명되고 있습니다. Keratomileusis(LASIK)는 수술 옵션 중 가장 일반적으로 수행되는 수술이었습니다.
세계보건기구(WHO)의 2021년 10월 보도 자료에 따르면, 약 8,840만명이 미대처의 굴절 이상으로 실명에 시달렸습니다. Medicine에서 발표된 조사 연구에 따르면 모든 참가자 중 23.0%가 나쁜 눈으로 20/40보다 나쁜 교정 VA(UCVA)를 나타내고, 6.0%가 경미한 시력 장애(PVAI)를 나타내고, 7.0%가 중등도 PVAI를 나타내었고, 0.2%가 더 나은 눈으로 심한 PVAI를 보였고, 46.9%가 비정상적인 UCVA를 보였습니다.
2021년 9월의 Cataract & Refractive Surgery Today의 기사에서는 굴절 교정의 장래에 대해 언급했습니다. 스튜디오와 같은 기술의 개발로 치료 옵션이 늘어나고 외과의사가 환자에게 제공할 수 있는 커스터마이즈 수준이 향상되었음을 보여주고 있습니다.
안과용 레이저의 제조에 있어서 고도로 선진적인 기술과 시스템 채용 증가, 안과용 레이저의 기술적 진보는 북미에서 시장 성장을 뒷받침할 것으로 예측되고 있습니다.
미국 질병 예방관리센터(CDC)가 2022년 2월에 발표한 보도자료에서는 가장 흔한 안장애와 안질환의 유병률 추정치가 제시되어 있습니다. 하지만 시력장애를 가지고 있으며 그 중 약 100만명이 실명하고 있습니다. 40세 이상의 23.9%강이 근시(약 3,400만명)입니다. 지방 단백질인 지질이 돌진을 구성하고 있기 때문에 이러한 안 질환의 유병률 증가는 이러한 질환의 치료를 위한 안과용 레이저 수요를 증가시킬 것으로 예상됩니다.
제품 승인도 시장 성장의 요인 중 하나입니다.
따라서 안과용 레이저를 포함한 수술의 필요성이 증가하고 의료 부문에서 R & D 증가는 이 지역 시장 성장을 가속하는 것으로 알려져 있습니다.
안과용 레이저 시장은 중등도의 경쟁이며, 여러 대형 기업으로 구성되어 있습니다. & Johnson Surgical Vision Inc., Bausch Health Companies Inc.(Bausch & Lomb Incorporated), Ellex Medical Lasers Limited, IRIDEX Corporation 등이 있습니다.
The Ophthalmic Lasers Market size is estimated at USD 1.56 billion in 2025, and is expected to reach USD 1.96 billion by 2030, at a CAGR of 4.7% during the forecast period (2025-2030).
The healthcare system witnessed enormous challenges as a result of the COVID-19 pandemic. All outpatient treatments were postponed or restricted during the COVID-19 pandemic to reduce the risk of viral transmission, as most chronic therapies were regarded as non-urgent. An article published in the Journal of Ophthalmic and Vision Research in December 2021 indicated that COVID-19 had caused ocular problems both directly and indirectly, and the further causes of concern are side effects of COVID-19 treatment and indirect consequences of lockdowns and shelter-in-place orders. The article also stated that the huge morbidity and death toll imposed by the pandemic has led to the adoption of life-saving treatment protocols with the downside of complications. Such hindrances are affecting the growth of the ophthalmic lasers market. However, the market is opening up, and with product launches and other initiatives, it is expected to grow during the forecast period.
According to the WHO 2021, around the world, at least 2.2 billion people have near or distant vision impairment. In at least around 1 billion or almost half of these cases, vision impairment could have been prevented or has yet to be addressed. As per the same source, vision impairment poses a global financial burden associated with vision impairment from uncorrected myopia (USD 244 billion) and presbyopia (USD 25.4 billion). The large prevalence of ophthalmic disorders around the world is adding to the growth of the ophthalmic lasers market.
Similarly, in January 2022, a press release by the World Economic Forum stated that rates of short-sightedness (myopia) are rising dramatically. By 2050, it's even predicted that half of the world's population would be short-sighted. These rates alone have risen in the past 50 years in Europe. According to the study, women were 24% more likely than men to develop myopia as children, but they were 12% less likely to do so as adults. It's unclear why this is the case, but it could be because men and women endure different hormonal shifts or different lifestyles. Thus, the increasing prevalence of myopia is expected to increase market growth during the forecast period as the patient often requires surgical treatments which involve ophthalmic lasers.
Initiatives by key market players are further expected to increase market growth during the forecast period. In April 2022, Nova Eye Medical launched its next-generation canaloplasty device, iTrack Advance, in select markets in Europe and Asia-Pacific. The iTrack Advance features include a proprietary illuminated fiber optic tip of the original iTrack device to allow the surgeon to continuously monitor the location of the device in Schlemm's canal. Thus, such initiatives are expected to increase market growth.
However, the high cost associated with laser therapies and the low availability of skilled practitioners are expected to restrict the growth of the studied market over the forecast period.
The refractive error corrections segment holds the major share in the ophthalmic lasers market. An article published in the journal of Annals of Medicine and Surgery in December 2021 indicated that refractive errors are the most common vision problem and prove to be a significant health issue. The article aimed to determine the awareness of refractive surgery. As per the article, Laser-assisted In Situ Keratomileusis (LASIK) was the most commonly performed procedure among surgical options. The increasing prevalence of ophthalmic lasers in refractive error corrections is expected to aid the growth of the segment in the ophthalmic lasers market during the forecast period.
According to the October 2021 press release by the World Health Organization, approximately 88.4 million people suffer blindness due to unaddressed refractive errors. Similarly, according to the research study published in May 2021, in the National Library of Medicine, from the total participants, 23.0% presented uncorrected VA (UCVA) was worse than 20/40 in worse eye, 6.0% presented mild presenting visual acuity impairment (PVAI), 7.0% presented moderate PVAI, 0.2% presented severe PVAI in the better eye, and 46.9% presented abnormal UCVA. Hence, owing to the high prevalence of refractive errors, the segment is expected to grow over the forecast period.
An article by Cataract & Refractive Surgery Today in September 2021 discussed the future of refractive correction. The article showed that the development of procedures such as SMILE and technologies such as Contoura Vision and iDesign Refractive Studio increased the number of treatment options and the level of customization that surgeons can offer to patients. The rise in the development of refractive corrective surgeries in recent years is adding to the growth of the ophthalmic lasers market over the forecast period.
The rise in the adoption of highly advanced techniques and systems in the manufacturing of ophthalmic lasers and the technological advancements made in ophthalmic lasers are expected to boost the growth of the market in the North American region. High awareness of the availability of innovative vision corrective surgeries in the medical field among the population contributes to the high market growth in the region.
A press release published in February 2022 by the Centers for Disease Control and Prevention (CDC) offered prevalence estimates for the most common eye disorders and eye diseases. Nearly 12 million adults in the United States who are 40 years and above of age have vision impairment, and about a million of them are blind. Every third American has astigmatism, which affects around 1 in 3 people. Over the age of 40, 8.4% of the population suffers from farsightedness (over 14.2 million people). A little over 23.9% of those over 40 have nearsightedness (about 34 million people). Another 7.3 million people experience visual issues brought on by massive drusen deposits, which are white or yellow deposits that develop behind the retina. Lipids, which are fatty proteins, make up drusen. Thus, such an increasing prevalence of eye diseases is expected to increase the demand for ophthalmic lasers for the treatment of such diseases.
Product approvals are another factor in market growth. For instance, in December 2021, LASEROPTEK Co., Ltd. received 510(k) clearance from the US Food and Drug Administration (FDA) for its PicoLO Premium picosecond pulse Nd: YAG laser. The approvals of such innovative products in the United States are expected to boost the growth of the market during the forecast period.
Thus the increasing necessity for surgeries involving ophthalmic lasers and increasing research and development in the healthcare department are known to propel the growth of the market in this region.
The ophthalmic lasers market is moderately competitive and consists of several major players. In terms of market share, few of the major players currently dominate the market. With the rising incidence of ophthalmic cases and increasing geriatric population, few other smaller players are expected to enter the market. Some of the major players in the market are Novartis AG (Alcon Laboratories Inc. ), Johnson & Johnson Surgical Vision Inc., Bausch Health Companies Inc. (Bausch & Lomb Incorporated), Ellex Medical Lasers Limited, and IRIDEX Corporation, among others.